AI Stock Cellebrite Fights For Support At Key Level After 65% Rally

Blockhead
2024-11-14

Artificial intelligence leader Cellebrite (CLBT) is fighting for support at its key 50-day line following last week's rally to new highs. The AI stock is one of the best ideas to watch on Investor's Business Daily's Stock Spotlight screen.

Israel-based Cellebrite is a digital intelligence company that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data.

X
Indexes Hold Firm After Inflation Data: Flutter, Cloudflare, Burlington Stores In Focus
See All Videos
NOW PLAYING Indexes Hold Firm After Inflation Data: Flutter, Cloudflare, Burlington Stores In Focus

In the latest quarter, reported on Nov. 6, Cellebrite earned 14 cents per share on sales of $106.9 million, year-over-year increases of 56% and 27%, respectively.

"We delivered a strong third-quarter performance that exceeded our expectations thanks to increasing traction with our AI-driven Case-to-Closure platform, the impact of our ongoing investment in market-leading innovation and solid execution on all fronts," Chief Executive Yossi Carmil said in the news release.


Nvidia, Apple And Tesla Highlight How To Handle This Market


AI Stock Pulls Back

Following a July 17 breakout move past a 12.67 handle entry, the AI stock has rallied nearly 66% from that buy trigger. During that move, the stock found support at its 10-week line a number of times, according to IBD MarketSurge analysis.

That indicates institutions are using the 10-week line as a level to support the stock. Look for that support to continue as the stock pulls back again to that level. However, if the stock breaks the 10-week line in heavy volume, that's a critical sell signal.

The stock's relative strength line hit a new high last week, reiterating the AI stock as a market leader. While it has pulled back during the recent Trump rally, it hasn't flashed any immediate red flags. The RS line measures a stock's price action vs. the S&P 500.

IBD Stock Checkup shows that Cellebrite stock boasts a strong 97 out of a best-possible 99 IBD Composite Rating. That makes the AI stock one of the best ideas to watch right now.

Be sure to follow Scott Lehtonen on X at @IBD_SLehtonen for more on the Dow Jones Industrial Average and the stock market today.

YOU MAY ALSO LIKE:

Check Out IBD's New Exposure Levels To Help You Stay In Step With The Market Trend

Top Growth Stocks To Buy And Watch

Learn How To Time The Market With IBD's ETF Market Strategy

Find The Best Long-Term Investments With IBD Long-Term Leaders

Spot Buy Points And Sell Signals With MarketSurge Pattern Recognition

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10